Vistide
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I
| Lot or serial number | Brand name | Companies | Dosage form | DIN, NPN, DIN-HIM | Strength |
|---|
| B1207217A | A. Vistide | - Recalling Firm
- Gilead Sciences
- 333 Lakeside Drive
- Foster City
- 94404
- California
- UNITED STATES
- Marketing Authorization Holder
- N/A
| Intravenous infusion | Nil | 75 mg / mL |
Recalled Products
A. Vistide
During secondary packaging run on January 29, 2013, of another sub-lot (B120217K), vials with floating particulate matter were noted.
Shipped to 12 Canadian hospitals:
-
Alberta Children's Hospital (Calgary)
-
Children’s and Women’s HC of BC (Vancouver)
-
Canadian Forces Medical Center (Petawawa ON)
-
Winnipeg HC Center
-
Hull Hospital (Gatineau)
-
Chaleur Regional Hospital (Bathurst NB)
-
Hotel Dieu of Quebec City
-
Peter Lougheed Center (Calgary)
-
Princess Margaret Hospital (Toronto)
-
Royal Alexandra Hospital (Edmonton)
-
Royal University Hospital (Saskatoon)
-
Vancouver General Hospital